The year in charts

The year in charts

Tuesday, April 25, 2023 @ 7:00 am

Capital investments in Swiss biotech companies 2012-2022

Revenues, R&D expenses, profit/loss, liquidity 2020-2022

Total Swiss Biotech Companies

Revenues, R&D expenses, profit/loss, liquidity 2020-2022 — Note: The 2022 data in above tables is based on information that was available up until March 31, 2023. At this time, some of the companies had not yet disclosed
their financial figures for 2022. Therefore some figures were carefully extrapolated on the basis of the latest interim data publicly available (i.e. Q3 or Q4 2022).

Revenues, R&D expenses, profit/loss, liquidity 2020-2022

Public Swiss Biotech Companies

Revenues, R&D expenses, profit/loss, liquidity 2020-2022

Private Swiss Biotech Companies

Number of biotech companies in Switzerland 2013-2022

Number of employees in Swiss R&D biotech companies 2020-2022

Tags

You may also be interested in

Security alerts: Fraudulent emails impersonating the Swiss Biotech Association

We track and escalate fraud campaigns that target Swiss Biotech Association members and Swiss Biotech Day participants. Current campaigns are listed in the box below and updated as new ones appear. The guidance applies to all of them. Please read it carefully and share it within your organization.
September 7, 2026

Newron flash update - Jumping the FDA hurdles should be manageable

October 11, 2026

Pharvaris: Phase 3 study shows efficacy in angioedema attacks treatment

Results from RAPIDe-3 demonstrate that treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours) and to complete symptom resolution (11.95 hours) Deucrictibant IR showed a well-tolerated safety profile NDA and MAA of deucrictibant IR for the on-demand treatment of HAE attacks under review by regulatory authorities
October 8, 2026

abc biopply and VoxCell partner on vascularized tissue models

abc biopply AG, Europe's first fully integrated Organoid CRO, and VoxCell BioInnovation Inc., a Canadian company and pioneer in bioprinted vascularized and perfusable tissue technologies in drug development, today announced the signing of a Letter of Intent (LOI) to explore a strategic collaboration focused on expanding the capabilities and accessibility of advanced human-relevant preclinical mode
October 8, 2026

Pharvaris: Study identifies gaps in hereditary angioedema care

Findings highlight opportunities for further improvement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options
October 5, 2026

ten23 health: Aseptic manufacturing capacity expanded in Visp

VIVA2 Expansion: ten23 health launches advanced high precision large-scale aseptic syringe, cartridge and vial filling Line 2, supporting customers through commercial scale-up.
October 5, 2026